BPC-157 vs TB-500: An Honest Evidence Comparison
Both are popular recovery peptides with strong animal data and little human evidence. TB-500's parent peptide reached early human trials (Grade C) versus BPC-157's Grade D. Neither is FDA-approved.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
BPC-157 and TB-500 are both recovery peptides with promising animal data and very limited human evidence. TB-500's parent peptide (thymosin beta-4) reached early human trials, so we grade it C versus BPC-157's D, but neither is FDA-approved, both are banned in sport, and both were under FDA compounding review in July 2026.
| BPC-157 | TB-500 | |
|---|---|---|
| Best studied for | Tendon, gut and tissue healing | Cell migration, wound and cardiac repair |
| Mechanism | Angiogenesis / VEGF, nitric oxide | Actin regulation / cell migration |
| Human evidence | Minimal (mostly animal) | Early trials of parent peptide (TB4) |
| FDA status | Not approved; under PCAC review | Not approved; under PCAC review |
| Banned in sport | Yes (WADA) | Yes (WADA) |
| Main safety flag | Theoretical angiogenesis/tumor concern | Poorly characterized in humans |
Same category, slightly different evidence
BPC-157 and TB-500 are usually mentioned together as recovery peptides, and both share the same core problem: extensive animal data that has not been confirmed in humans. The distinction worth understanding is that TB-500 is a fragment of thymosin beta-4 (TB4), and TB4 itself reached early-phase human trials for wound, cardiac and corneal repair. That is why we grade the TB-500 class C (Emerging Human Data) while BPC-157 sits at D (Preclinical Only).
The honest caveat on that distinction
The slightly higher grade for TB-500 should not be over-read. The human trials were for TB4, not the specific TB-500 fragment sold in the peptide market, and they were early-phase, not confirmatory. Neither compound has a completed randomized trial establishing recovery benefit in people, and neither is FDA-approved.
Safety and regulation
Both are prohibited in sport under WADA, and both were among the seven peptides the FDA reviewed at the July 2026 PCAC meeting, where briefing documents recommended against adding them to the compounding list. BPC-157 carries a specific theoretical concern around angiogenesis in the context of existing tumors; TB-500's main issue is simply how little its human safety has been characterized. For either, the biggest practical risk is unregulated research-chemical supply of unverified purity.
Bottom line
Neither is proven in humans for recovery. TB-500 grades slightly higher (C vs D) because its parent peptide reached early human trials, but the honest bottom line is that both are preclinical-stage, not FDA-approved, banned in sport, and were under active FDA review. In practice people often stack them rather than choose between them, though that combines two unproven compounds.
Frequently asked questions
Is BPC-157 or TB-500 better for healing?+
Neither is proven in humans. TB-500's parent peptide has slightly more early human data (Grade C vs D), but there is no completed human trial establishing either as an effective recovery treatment.
Can you take BPC-157 and TB-500 together?+
They are frequently stacked in community protocols, but that combines two compounds that are both unproven in humans and not FDA-approved. Any use should involve a licensed clinician, not research-chemical vendors.
Are BPC-157 and TB-500 legal?+
Neither is FDA-approved. Both have been available via compounding and the research-chemical market, both are banned in sport, and both were under FDA compounding review in July 2026.
Sources
- 1.July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee · U.S. Food & Drug Administration
- 2.WADA Prohibited List · World Anti-Doping Agency